EirGenix : Announcement of the Board of Directors resolved to update the vesting conditions of employee restricted stock awards in 2022.

 Announcement of the Board of Directors resolved
to update the vesting conditions of employee restricted
stock awards in 2022.

1.Resolution date of the board of directors:2022/04/19
2.Expected issue price:
  Grants will be made free of charge.
3.Expected total amount (shares) of issuance:
  850,000 common shares, each with a par value of NT$10.
  The actual number of shares to be issued will be resolved
  by the Board of Directors after the issuance of employee
  restricted stock awards ("RSAs") is approved at the
  shareholders' meeting and by the competent authority.
4.Vesting conditions:
  Employee must remain employed by the Company on the last date of
  each vesting period. During the vesting period, the employee may not
  breach any agreement with the company or violate the Company's
  employment agreement, service agreement, trust agreement,
  company governance best practice principles, ethical corporate
  management best practice principles, work rules, non-compete
  and non-disclosure agreement of the Company, or any agreement
  with the Company. Certain employee performance metrics
  and the Company's business performance metrics are to be met
  in the Employee Restricted Stock Awards Rules.
  Condition A: Employees on board at, or before the third quarter
    of 2022, 100% of shares will be vested at the end of same year.
  Condition B: Employees on board in the fourth quarter of 2022,
    100% of shares will be vested at the end of following year.
  Condition C: Employees on board between the first quarter to
    third quarter of 2023, 100% of shares will be vested
    at the end of same year.
  Condition D: Shares granted for employees 2021 personal
    performance and company performance rating over 2.5,
    will be vested 100%.
  Condition E: Shares granted for employees 2022 company
    performance rating over 2.0, and personal performance
    rating plus company performance rating total over 5.0
    will be vested 100%.
5.Measures to be taken when employees fail to meet the vesting
 conditions or in the event of inheritance:
  Where an executive fails to meet the vesting conditions,
  the Company will reclaim the granted RSAs and cancel the same
  at no extra cost to the Company; for exceptional events,
  including but not limited to inheritance, the Company will take
  measures as set forth in the Employee Restricted Stock Awards Rules.
6.Other issuance criteria:
  As set forth in the Employee Restricted Stock Awards Rules.
7.Qualification criteria for employees:
  Only the Company's and controlling and subordinate company's
  regular employees who are already employed on the date that RSAs
  are granted.
  The term" controlling and subordinate company" is recognized in
  accordance with the standard from Financial Supervisory Commission
  (official letter No.1070121068).
8.The reason the current issuance of RSA is necessary:
  To attract and retain talents and to encourage employees who
  contribute to the company's major operation goals.
9.Calculated expense amount:
  The total expenses are preliminarily estimated at approximately
  NT$80.333 million based on EirGenix 's outstanding shares of
  303,686,235 shares and 850,000 shares to be granted as RSAs,
  the average closing price of NT$94.51 per share in March 2022,
  and the calculation by the valuation model.
  The expenses are preliminarily estimated at approximately
  NT$58.596 million and NT$21.737 million from 2022 to 2023,
  respectively.
  Actual expenses will be calculated by the fair value
  on the given date and after recognizing related expenses
  in installments during the vested period.
10.Dilution of the Company's earnings per share (EPS):
   For the Company issuing RSAs, representing 0.28% of an
   aggregate number of all shares issued, the potential impact
   from the above-mentioned expenses to the Company's EPS
   is preliminarily estimated at approximately NT$0.193 and
   NT$0.071 from 2022 to 2023, respectively.
11.Other matters affecting shareholder's equity:
   There is no material impact on shareholders' equity.
12.Restrictions before employees meet the vesting conditions
 once the RSA are received or subscribed for:
   A.During the vesting period, the employee may not sell,
   pledge, transfer, give to another person,
   create any encumbrance on, or otherwise dispose of RSAs.
   B.Voting rights in Shareholders' Meeting:
   The same as common stock.
   C.Dividend: The same as common stock.
13.Other important terms and conditions (including stock trust
 custody, etc.):
  Granted RSAs will be deposited in a stock trust custody account.
14.Any other matters that need to be specified:
   If any revision or adjustment has to be made due to any
   instruction of the competent authority or amendment to the
   laws and regulations, then it is proposed that the
   Annual Shareholders' Meeting authorize the Board of Directors
   or the person authorized by the Board of Directors to handle
   all relevant matters regarding the granting of the RSAs.